Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients

Inclusion Criteria: For MS patients:

• 18 years and above
• Diagnosed with relapsing MS according to McDonald Criteria (2017)
• Not already vaccinated by RZV and willing to be vaccinated with RZV.
• At least 1 year on anti-CD20 treatment: 2 initial infusions of Ocrelizumab 300 mg (2weeks apart), one infusion of Ocrelizumab 600 mg 6 months apart, one infusion ofOcrelizumab 600 mg 12 months after initial infusions
• Informed consent as documented by signature For healthy controls
• Aged 50 to 59
• Not already vaccinated by RZV and willing to be vaccinated with RZV
• Informed consent as documented by signature

Exclusion Criteria:

• Recent MS relapse in the 6 weeks preceding planned vaccination
• Ongoing signs of febrile or non-febrile infection at the time of vaccination
• Recent pregnancy with delivery in the six months preceding vaccination and/or plannedpregnancy in the six months following RZV vaccination
• Immunosuppression from the following: HIV infection, current active systemicauto-immune disease (other than MS), current malignant neoplasm; primaryimmunodeficiency; recent solid or bone-marrow transplant or any transplant stillrequiring immunosuppressive therapy; conditions requiring medication withimmunosuppressive drugs
• Having received a vaccine in the last month
• Having received a shingles vaccine within one year
• Presented with herpes zoster in the previous year
• Contra-indication to RZV
• Unable to provide informed consent or inability to follow the procedures of the study,e.g. due to language problems, psychological disorders, dementia.
• Participation in another study with investigational drug within the 30 days precedingand during the present study.